Hospital for Sick Children, and the University of Toronto, Ontario, Canada.
Hospital for Sick Children, Toronto, Ontario, Canada.
J Am Acad Child Adolesc Psychiatry. 2023 Jun;62(6):696-698. doi: 10.1016/j.jaac.2023.01.016. Epub 2023 Feb 22.
Pediatric anxiety disorders (AD) are prevalent disorders with an impact on all aspects of a child's life and functioning. Although evidence supports commonly used treatments, there are notable concerns with the research to date. Heterogeneity in outcome selection, measurement, analysis, and reporting is a contributing factor to the hinderance of the translation of research into clinical practice. Recognition for outcome standardization in pediatric mental health disorders is evolving and there are several initiatives of importance, including the International Consortium for Health Outcomes Measurement (ICHOM), which has developed standardized outcome sets for use in the routine clinical mental health treatment of children and adolescents. Similarly, the International Alliance of Mental Health Research Funders advocate for use of 1 specific outcome measurement instrument (OMI) in the youth mental health research that they fund. Development of a Core Outcome Set (COS), a minimal set of outcomes that should be measured and reported in clinical trials, has been a solution in other areas of medicine to address heterogeneity in outcome selection and measurement across trials. The Core Outcomes and Measures in Pediatric Anxiety Clinical Trials (COMPACT) Initiative will develop a harmonized, evidence- and consensus-based COS that is meaningful to youth and families for use in future trials in pediatric AD.
儿科焦虑障碍 (AD) 是一种普遍存在的疾病,会影响儿童生活和功能的各个方面。尽管有证据支持常用的治疗方法,但迄今为止的研究仍存在明显的问题。结果选择、测量、分析和报告的异质性是阻碍研究转化为临床实践的一个因素。儿科心理健康障碍的结果标准化已经得到认可,并且有几个重要的倡议,包括国际健康结果测量联合会 (ICHOM),该联合会已经为儿童和青少年的常规临床心理健康治疗制定了标准化的结果集。同样,国际精神健康研究资助者联盟主张在他们资助的青年精神健康研究中使用 1 种特定的结果测量工具 (OMI)。核心结局集 (COS) 的开发,即临床试验中应测量和报告的最小结局集,是解决其他医学领域中试验间结局选择和测量异质性的一种方法。儿科焦虑症临床试验的核心结局和措施 (COMPACT) 倡议将制定一个协调一致的、基于证据和共识的 COS,该 COS 对青少年及其家庭有意义,可用于未来儿科 AD 的临床试验。